Login to Your Account

Financings Roundup

Bringing RNA Back, Mirna Gets $34.5M in Series C

By Catherine Shaffer
Staff Writer

Wednesday, October 24, 2012
Amidst a venture capital climate that could most charitably be described as "tough" for early stage biotech, Mirna Therapeutics Inc., of Austin, Texas, completed a $34.5 million Series C financing led by Sofinnova Ventures, with New Enterprise Associates, Pfizer Ventures, Osage University Partners, Correlation Ventures and some existing investors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription